ArticleDie Ophthalmologie2026
[Real-world experience with aflibercept 8 mg for treatment of neovascular age-related macular degeneration after 12 months].
Article in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe phase 3 clinical trial PULSAR demonstrated extended treatment intervals with aflibercept 8 mg in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) in a large proportion of the cohort, with good drug safety. Early clinical experience in real-world settings confirmed the efficacy in both treatment-naïve and pretreated patients but no data on longer observation periods are available yet.
objectiveThe aim of the study was to investigate the efficacy, treatment frequency and tolerability of aflibercept 8 mg over a period of 12 months in a group of pretreated nAMD patients. MATERIAL AND
methodsA retrospective study of 73 eyes with nAMD and pretreatment with anti-VEGF switched to aflibercept 8 mg. Eyes were initially uploaded with 3 monthly intravitreal injections (IVI), followed by a pro re nata (PRN) regimen. Outcome parameters included visual acuity development and central retinal thickness (CSRT) after upload and 12 months, treatment frequency in the year before and after switching to aflibercept 8 mg, and the overall tolerability of the drug.
resultsOf the initial 73 eyes, 27 eyes (37.0%) were still receiving aflibercept 8 mg after 12 months. In these eyes CSRT was reduced from 387.9 ± 138.4 µm initially to 305.5 ± 93.2 µm after upload and 328.9 ± 105.6 µm after 12 months (p < 0.001). Visual acuity remained stable (p > 0.05). Compared to the year prior to switching, the injection frequency was reduced from 8.2 ± 2.1 to 6.9 ± 1.0 IVIs (p < 0.005). During the observation period, a total of 5 eyes (6.8%) developed noninfectious intraocular inflammation (IOI), with all cases completely regressing with topical treatment.
conclusionThese results confirm a good efficacy of aflibercept 8 mg for the treatment of nAMD with reduced injection frequency after 12 months of treatment in a portion of pretreated eyes that were often previously refractory to treatment. Longer observation intervals and experience with other treatment regimens are necessary to confirm this observation.
Indexed as
Identifiers
42397425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.